Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
CA 2106080 C · Owner: United States Of America, Represented By The Secretary, Department Of He Alth And Human Services (The) · Inventors: Parada, Luis F.; Martin-Zanca, Dionisio; Kaplan, David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that may be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzeimer's and Huntington's by detecting NGF-trk receptor pairs.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 16, 1992 and granted September 15, 1998. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 16, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 16, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.